Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marcio Silva De'Souza
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 168
- Beta
- 2.84
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 94.22
Financials
Revenue
$0.00-100.0%Net Income
$-94.23MEBITDA
$-94.20MFree Cash Flow
$-82.52MEPS (diluted)
$-3.23Shares Outstanding (diluted)
29.18M+29623.5%Operating Expenses
$106.91MCash & Debt
$745.32MReturn of Capital
$0.00Revenue by Segment (annual)
$11.20MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-303.27M | $-13.48 |
| 2024 | $8.55M | $-182.82M | $-10.21 |
| 2023 | $2.45M | $-123.28M | $-18.69 |
| 2022 | $0.00 | $-214.03M | $-69.33 |
| 2021 | $0.00 | $-167.06M | $-58.96 |
| 2020 | $0.00 | $-61.82M | $-103.61 |
| 2019 | $0.00 | $-35.51M | $-348.24 |
| 2018 | $0.00 | $-26.54M | $-306.73 |
Valuation
PRAXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
160+166.16%Social Signal Score
Mentions (13)
- News (RSS)seekingalpha·3d ago·Positive
Praxis Precision: Steady Hands For A Shaky PDUFA Season (Initiating With A Speculative Buy)
View source ↗ - Newsseekingalpha.com·3d ago·Neutral
…ky PDUFA Season (Initiating With A Speculative Buy) I initiate Praxis Precision Medicines at a speculative Buy, with a $410 price target implying roughly 26% upside. PRAX's two NDAs cleared mid-cycle reviews without major safety or efficacy concerns, but ulixacaltamide's tolerability and potential label restrictions remain key risks. Ulixacaltamide drives the thesis; positive EMERALD data could expand relutrigine into the broader 200,000-patient DEE market.
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Praxis Precision Medicines, Inc. (PRAX) Presents at UBS Global Biopharma Conference 2026 Transcript Praxis Precision Medicines, Inc. ( PRAX ) UBS Global Biopharma Conference 2026 November 16, 2026 5:40 AM EST Company Participants Marcio Souza - President, CEO & Director Conference Call Participants Joon Lee - UBS Investment Bank, Research Division Presentation Joon Lee UBS Investment Bank, Research Division Okay. Well, thank you, everyone, for joining us for this inaugural UBS Global Biopharma C…
View source ↗ - News (RSS)seekingalpha·6d ago·Neutral
Praxis Precision Medicines: No Material Changes After Q3 And Investor Day (Rating Kept)
View source ↗ - News (RSS)economictimes·7d ago·Neutral
Stock splits & dividends: MRF among 31 firms to turn ex-record date As many as 31 companies including Cochin Shipyard, Oil India, MRF, Power Finance Corporation (PFC), Manappuram Finance and others, have scheduled record dates for dividends and stock splits during the week between November 16 (Monday) to November 20 (Friday).To be eligible for these corporate actions, investors must hold the shares in their demat accounts as of the respective record dates. The list is tentative, as more companie
View source ↗ - News (RSS)investing·10d ago·Negative
Praxis outlines launch plans for two drug candidates
View source ↗ - News (RSS)seekingalpha·11d ago·Positive
Praxis Precision Medicines, Inc. (PRAX) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
View source ↗ - News (RSS)zerohedge·12d ago·Positive
Why Are So Many British Charities Lobbying For Open Borders? Why Are So Many British Charities Lobbying For Open Borders? Authored by Joanna Williams via Spiked,Next time someone rattles a tin, and you reach for a couple of quid to help rough sleepers, starving donkeys or sick children, think twice. It's long been clear that major charities are run like businesses; less well known is that they receive vast sums of taxpayers' money. And while it might be understandable that big charities try to i
View source ↗ - Newsglobenewswire.com·13d ago·Positive
…t at the Guggenheim Biotech Summit today, November 9 at 9:30am ( register here ) BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today provided a corporate update and reported financial results for the third quarter of 2026. “We are entering a defining period for Praxis, with two key regulatory milestones ahead and the opportunity to become a comm…
View source ↗ - News (RSS)seekingalpha·71d ago·Positive
Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)
View source ↗ - Newsseekingalpha.com·71d ago·Positive
…ine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA dates, target large, underserved CNS markets with combined peak sales potential exceeding $15 billion. PRAX's $1.4 billion cash position supports a commercial buildout and reduces near-term capital market risk, with further upside from potential out-licensing and priority review vouchers.
View source ↗ - News (Marketaux)gurufocus.com·82d ago·Positive
Velan Capital Investment Management LP Expands Edesa Biotech Inc (EDSA) Stake The firm's top holdings include Sutro Bi[+183 characters]
View source ↗ - News (RSS)investing·97d ago·Neutral
Praxis Precision Medicines stock hits 52-week high at 388.27 USD
View source ↗
Earnings
Thu, Feb 18(in 3 months)
Consensus estimate $-4.08 per share
Typical surprise +2.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$-3.23 vs $-3.54beat
- Thu, Aug 6$-2.87 vs $-3.67beat
- Thu, May 7$-3.20 vs $-3.58beat
- Thu, Feb 19$-3.50 vs $-3.13miss
- Wed, Nov 5$-3.36 vs $-3.45beat
- Mon, Aug 4$-3.31 vs $-3.40beat
Estimates and results for PRAX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PRAX officers and directors.
- Bought
- —
- Sold
- $8.5m
0 trades
16 trades
- Desimone Jillsold
- Desimone Jillsold
- Desimone Jillsold
- Desimone Jillsold
- Desimone Jillsold
- Desimone Jillsold
- Desimone Jillsold
- Desimone Jillsold
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Oct 12, 2026 (13d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Sep 7, 2026 (39d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
